AOK Bayern Die Gesundheitskasse Tender

Contract notice: Open house drug discount agreements dabigatran etexilate, ATC B01AE07 It is not an open procedure, but a so-called open-house model! The form for the open procedure is only used because there is no form for the open-house model. Contracts that are concluded in the open-house model are not subject to public procurement law due to the lack of a selection decision. Submission to public procurement regulations is not associated with the use of this form. AOK Bayern intends to conclude non-exclusive discount agreements on the active substance dabigatran etexilat, ATC B01AE07, with all interested pharmaceutical companies in accordance with Section 130a Paragraph 8 of the Social Code Book V. AOK Bayern offers all interested pharmaceutical companies that meet the eligibility requirements listed below the opportunity to conclude identical and non-individually negotiable discount agreements. The earliest possible start of the contract is May 1st, 2022, all contracts end on April 30th, 2024. A contract can be concluded at any time during this period, but no later than 03/05/2024. The contracts can be terminated with one month's notice to the end of the month. Upon the entry into force of a federal or state-specific, In the case of a discount agreement concluded in an open procedure for medicinal products with the active substance that is the subject of the order, the open-house agreements automatically expire for the corresponding term. A contract will be concluded with all interested pharmaceutical companies that demonstrate their eligibility by completing and signing a self-declaration of reliability.